Personalis Stock Price, News & Analysis

Personalis, Inc. (NASDAQ: PSNL) has published a study in Nature Communications detailing the development of DASH, a machine learning-based algorithm for detecting human leukocyte antigen loss of heterozygosity (HLA LOH). This biomarker is crucial for cancer immunotherapy and helps cancer cells evade immune detection. The study showed DASH's increased sensitivity in identifying HLA LOH across various tumor types among 610 patients, with notable prevalence in non-small cell lung cancer (24%), cervical cancer (38%), and head and neck cancers (40%).

Personalis, Inc. (NASDAQ: PSNL) announced the issuance of US Patent No. 11,299,783 on April 12, 2022, concerning its NeXT Personal minimal residual disease (MRD) detection platform. This patent covers innovative methods for a personalized assay, enhancing tumor burden measurement and tracking of tumor variants. The NeXT Personal platform uniquely integrates detection and characterization of tumors, positioning it as a potential new standard in cancer monitoring. Personalis now holds 19 patents in genomic sequencing and analysis, with over 25 additional applications pending.

Personalis, Inc. (NASDAQ: PSNL) announced a collaborative study with Merck KGaA, presented at the American Association for Cancer Research Annual Meeting 2022 from April 8-13. This study utilizes advanced transcriptome and exome data to enhance colorectal cancer molecular subtyping. The research aims to integrate mutation profiles for better subtype identification in late-stage CRC. Richard Chen, MD, emphasized the potential of this collaboration in advancing cancer diagnostics and treatment strategies.

Personalis, Inc. (NASDAQ: PSNL), a leader in cancer genomics, announced its participation at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 2:15 p.m. Eastern Time. This event highlights the company's innovation in precision cancer therapies and diagnostics through its Personalis NeXT Platform®, which analyzes all human genes and the immune system from a single sample. Personalis is committed to advancing cancer sequencing with a focus on clinical accuracy, quality, and efficiency.

Personalis, Inc. (Nasdaq: PSNL) has appointed Karin Eastham as the new Board Chair, effective May 17, 2022. Eastham, who joined the Board in 2019, has a notable history with Illumina and Veracyte, contributing to substantial growth in both organizations. Her leadership is expected to enhance the company’s oncology diagnostics business, leveraging advanced technologies already generating rapid revenue growth from pharmaceutical partnerships. Former Chair Jonathan MacQuitty will not seek re-election but will continue as a strategic advisor.

Personalis, Inc. (Nasdaq: PSNL) announced its participation at the AACR Annual Meeting 2022, presenting five scientific posters from April 8-13, 2022. The company aims to showcase advances in precision oncology with a focus on genomic data and innovative techniques like the NeXT Liquid Biopsy and ImmunoID NeXT Platform. These studies highlight the ability to monitor somatic mutations in cancer patients and assess immune cell compositions, enhancing understanding of tumor biology and treatment resistance.

Personalis, Inc. (Nasdaq: PSNL) reported Q4 2021 revenue of $20.7 million, a 3% increase from Q4 2020. Revenue from biopharma customers, excluding the VA MVP, surged 102% to $15.4 million. However, revenue from the VA MVP fell 58% to $5.3 million. For the full year, revenue reached $85.5 million, a 9% increase. Operating expenses were $28.2 million in Q4, leading to a net loss of $20.2 million. The company forecasts $67.0 million in revenue for 2022, with a net loss between $110.0 million and $115.0 million.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced cancer genomics, announced that its management will present at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 2:10 p.m. Eastern Time. The company specializes in providing precision cancer therapies and diagnostics through its Personalis NeXT Platform, offering insights into all human genes and the immune system from a single sample. The clinical laboratory is highly accredited, emphasizing quality and efficiency.

Personalis, Inc. (NASDAQ: PSNL) announced a strategic partnership with the Moores Cancer Center at UC San Diego Health to enhance clinical diagnostic testing for patients with advanced tumors. This collaboration aims to utilize Personalis' advanced genomic tumor profiling test to inform FDA-approved therapy decisions and clinical trial options. The partnership also focuses on developing novel biomarkers and conducting research on a liquid biopsy assay that significantly improves sensitivity for detecting minimal residual disease and cancer recurrence, enhancing patient care.